Achaogen is a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of innovative antibacterials to treat multi-drug resistant (MDR), gram-negative infections. The Company is developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections due to MDR Enterobacteriaceae, including CRE. Achaogen is also developing an oral antibacterial candidate, C-Scape, a combination of an approved beta-lactam and an approved beta-lactamase inhibitor with the potential to treat patients with complicated urinary tract infections (cUTI) due to MDR pathogens. Achaogen's research and development pipeline includes additional gram-negative programs such as inhibitors of LpxC, an enzyme essential for the synthesis of the outer membrane of gram-negative bacteria, and a therapeutic antibody program.

Company Growth (employees)
South San Francisco, US
Size (employees)
194 (est)+84%
Achaogen was founded in 2004 and is headquartered in South San Francisco, US

Achaogen Office Locations

Achaogen has an office in South San Francisco
South San Francisco, US (HQ)
371 7000 Shoreline Ct

Achaogen Financials and Metrics

Achaogen Financials

Achaogen's revenue was reported to be $41.8 m in FY, 2016

Revenue (Q2, 2017)

1.3 m

Net income (Q2, 2017)

(26.1 m)

EBIT (Q2, 2017)

(29.8 m)

Market capitalization (13-Dec-2017)

472.3 m

Cash (30-Jun-2017)

144 m
Achaogen's current market capitalization is $472.3 m.
USDFY, 2014FY, 2015FY, 2016


20 m26.1 m41.8 m

Revenue growth, %


R&D expense

30.1 m40.2 m74 m

General and administrative expense

9.6 m12.4 m17.1 m
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017


6 m5.2 m4.5 m4.9 m12 m4.5 m5.8 m9.1 m16 m7.5 m1.3 m

R&D expense

6.6 m6.2 m10.7 m7.9 m10.1 m10 m13.9 m21.7 m20.5 m18.6 m22.2 m

General and administrative expense

2.6 m2.3 m2.2 m3.2 m2.9 m3 m3.8 m4 m4.5 m6.8 m8.9 m

Operating expense total

9.2 m8.5 m12.9 m11.1 m13 m13 m17.7 m25.7 m25 m25.3 m31.1 m
USDFY, 2014FY, 2015FY, 2016


18.9 m20.3 m119 m

Accounts Receivable

301 k


210.1 m

Current Assets

69.4 m65.5 m160.3 m
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017


84.9 m74.5 m46.9 m22.9 m39.5 m35.1 m19.4 m54.6 m41.8 m37.6 m144 m

Current Assets

91.1 m80.4 m76.6 m66.7 m66.6 m76.1 m57.9 m81.3 m79.4 m147.1 m248.2 m


662 k615 k662 k648 k902 k836 k1.1 m995 k1 m8.4 m11.4 m

Total Assets

92 m81.2 m77.4 m67.5 m67.7 m77.4 m59.2 m82.3 m80.7 m155.8 m263.2 m
USDFY, 2014FY, 2015FY, 2016

Net Income

(20.2 m)(27.1 m)(71.2 m)

Depreciation and Amortization

358 k426 k441 k

Cash From Operating Activities

8.1 m1.4 m(46.9 m)

Purchases of PP&E

(340 k)(606 k)(901 k)
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(8.3 m)(6.2 m)(886 k)(8.8 m)(12.2 m)(18.3 m)(11 m)(33.3 m)

Accounts Payable

2.6 m6.2 m3.9 m4 m5.3 m6.6 m6.1 m7.6 m11.6 m
Y, 2017

Financial Leverage

1.5 x
Show all financial metrics

Achaogen Market Value History

Achaogen's Web-traffic and Trends

Achaogen Online and Social Media Presence

Achaogen Company Life and Culture

You may also be interested in